Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar

Affiliations

¹ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address: spal@coh.org.
² Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
³ Department of Internal Medicine, Istanbul Medeniyet University Goztepe Research and Training Hospital, Dumlupınar, Istanbul, Turkey.
⁴ Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham Cancer Center, Birmingham, AL, USA.

Comment

Sumanta K Pal et al. Lancet Oncol. 2016 Nov.

. 2016 Nov;17(11):1477-1478.

doi: 10.1016/S1470-2045(16)30493-4. Epub 2016 Oct 3.

¹ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address: spal@coh.org.
² Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
³ Department of Internal Medicine, Istanbul Medeniyet University Goztepe Research and Training Hospital, Dumlupınar, Istanbul, Turkey.
⁴ Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham Cancer Center, Birmingham, AL, USA.

No abstract available

Comment on

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T. Rini BI, et al. Lancet Oncol. 2016 Nov;17(11):1599-1611. doi: 10.1016/S1470-2045(16)30408-9. Epub 2016 Oct 3. Lancet Oncol. 2016. PMID: 27720136 Clinical Trial.